ASX · CSL.AX
CSL Limited
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
Loading market information…
ASX · TTX.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 05:11 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Tetratherix Ltd.’s quoted price sits in the upper half of its reported 52-week range, 31.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Tetratherix Ltd.’s next earnings report is currently expected on Mar 1, 2027, with estimated earnings per share of -A$0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tetratherix Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2015 and headquartered in Alexandria, Australia, Tetratherix Ltd. operates in the biomaterials and regenerative medicine sectors across both domestic and international markets. The company develops and supplies products using its proprietary Tetramatrix platform technology, with a focus on applications including bone regeneration, tissue spacing, and advanced tissue healing.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
A$2.26-A$0.06 (-2.59%)
Mesoblast Limited’s quoted price sits in the lower half of its reported 52-week range, 31.72% below the high.
A$0.91+A$0.03 (+2.84%)
PolyNovo Limited’s quoted price sits in the lower half of its reported 52-week range, 35.13% below the high.
A$0.55+A$0.02 (+2.8%)
Aroa Biosurgery Limited’s quoted price sits in the lower half of its reported 52-week range, 31.25% below the high.
A$0.55+A$0.02 (+2.8%)
Orthocell Limited’s quoted price sits in the lower half of its reported 52-week range, 56.18% below the high.
A$0.09A$0.00 (0.0%)
ReNerve Limited’s quoted price sits in the lower half of its reported 52-week range, 59.09% below the high.
A$0.40-A$0.02 (-4.76%)
Cambium Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 33.33% below the high.
A$0.10A$0.00 (0.0%)
Tissue Repair Ltd’s quoted price sits in the lower half of its reported 52-week range, 80.21% below the high.
